You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.

Cartisorb Bioiberica


Cartisorb® is indicated for adults to relieve light to moderate symptoms of osteoarthritis of the knee.

Information updated January 2019.

Composition and dose

Cartisorb® contains glucosamine sulfate as an active substances, and comes in boxes with 30 sachets, each of which contains 1,500 mg of powder for oral solution with a lemon flavour.

The therapeutic dose is 1 sachet per day, for at least 2 months.

Cartisorb® is a prescription drug, financed by Social Security, registered in Spain by the Spanish Agency of Medicines and Medical Devices (AEMPS).

It is also approved in other countries under other brand names. Please contact us for more information.  

Efficacy and safety

Clinical trials performed with glucosamine sulphate on patients with osteoarthritis have demonstrated that it significantly improves the symptoms of osteoarthritis such as pain and functional deficits1,2. This drug also features a carry over effect3. All this helps to improve the quality of life for patients with osteoarthritis.

Additionally, the safety of glucosamine sulphate has been shown in several publications1,2.



Cartisorb® is financed by Social Security